Deutsche Bank Aktiengesellschaft cut shares of Catalent (NYSE:CTLT – Get Rating) from a buy rating to a hold rating in a report published on Monday, The Fly reports. The firm currently has $29.00 target price on the stock, down from their prior target price of $55.00.
CTLT has been the subject of several other research reports. Bank of America downgraded shares of Catalent from a neutral rating to an underperform rating and set a $28.00 price objective for the company. in a research report on Monday, May 8th. Robert W. Baird lowered shares of Catalent from an outperform rating to a neutral rating and cut their price objective for the stock from $82.00 to $53.00 in a report on Monday, April 17th. William Blair downgraded Catalent from an outperform rating to a market perform rating in a research note on Friday, April 14th. Barclays cut their price target on Catalent from $70.00 to $40.00 in a research note on Monday, April 17th. Finally, StockNews.com raised Catalent to a sell rating in a report on Saturday, April 15th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average price target of $74.80.
Catalent Price Performance
Shares of NYSE CTLT opened at $33.19 on Monday. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.91 and a quick ratio of 1.38. Catalent has a 1-year low of $31.45 and a 1-year high of $115.33. The company has a market capitalization of $5.98 billion, a price-to-earnings ratio of 14.69, a PEG ratio of 2.38 and a beta of 1.17. The business has a 50-day moving average of $55.92 and a 200-day moving average of $53.74.
Insiders Place Their Bets
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of CTLT. Davidson Kempner Capital Management LP acquired a new stake in shares of Catalent in the first quarter valued at approximately $12,156,000. Advisor Partners II LLC grew its holdings in Catalent by 19.5% in the 1st quarter. Advisor Partners II LLC now owns 7,127 shares of the company’s stock worth $468,000 after buying an additional 1,163 shares in the last quarter. Ensign Peak Advisors Inc increased its position in Catalent by 4.2% in the 1st quarter. Ensign Peak Advisors Inc now owns 54,510 shares of the company’s stock valued at $3,582,000 after acquiring an additional 2,200 shares during the period. Mirova bought a new stake in Catalent during the 1st quarter valued at $103,000. Finally, Ossiam boosted its position in Catalent by 243.3% during the 1st quarter. Ossiam now owns 5,767 shares of the company’s stock worth $379,000 after acquiring an additional 4,087 shares during the period. 99.38% of the stock is owned by institutional investors and hedge funds.
Catalent Company Profile
Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- FREYR Battery Is An Interesting Play On EVs: At Rock Bottom
- Analysts Upgrade GXO Logistics, Its First Quarter Says It All
- The Bottom Is In For AppLovin; Reversal Is Next
- Exact Sciences Serves Investors Exactly What They Wished For
- Shockwave Medical, Fast Grower, In Boston Scientific’s Sights?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.